<DOC>
	<DOCNO>NCT00149006</DOCNO>
	<brief_summary>The present protocol design investigate potential application allogeneic cell-mediated immunotherapy metastatic solid tumor similarly well establish graft versus leukemia ( GVL ) effect patient hematologic malignancy . Patients metastatic solid tumor resistant conventional modality eligible participate treatment program base administration non-myeloablative immunotherapy ( i.e . fludarabine , Cytoxan ) follow interferon injection ; subsequently patient treat mismatched alloreactive donor lymphocyte activate vitro vivo rIL-2 . The aim study base recognition foreign tumor cell surface alloantigens .</brief_summary>
	<brief_title>Cell Therapy Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 ( rIL-2 ) Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Consenting patient ( age &lt; 70 ) eligible participation study involve selective antitumor immunotherapy provide follow criterion meet : Evidence cancer expect cure conventional modality Pediatric patient : Chemotherapyresistant neuroblastoma stage 4 sarcoma . Adult patient : Metastatic breast cancer , malignant melanoma , renal cell cancer select case ovarian cancer , gastrointestinal cancer , smallcell nonsmall cell lung cancer nonbulky metastatic disease , metastatic prostate cancer . Patients measurable disease evaluable response anticipate life expectancy &gt; 3 month . Patients must &gt; 2 week anticancer potentially immunosuppressive treatment . Adequate ambulatory performance status ( Karnofsky &gt; 80 % ; ECOG 01 ) enable outpatient treatment . Compliant cooperative patient anticipate evaluable response accord investigator 's assessment . HLAcompatible ( fully match single locus mismatch ) donor available allogeneic stem cell transplantation . Patients bulky disease patient brain metastasis resistant chemoradiotherapy . Patients significant history current evidence potentially severe cardiovascular lung disease , disease clinical condition may permit accomplish plan treatment draw conclusion . Hepatic and/or renal failure . Evidence serious active infection require antibiotic therapy . Pregnancy . Contraindication donation due donor disease : HIV1 ; hepatitis B surface antigen ( HBsAg ) positivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Metastatic solid tumor</keyword>
	<keyword>Mismatch allogeneic cell mediate immunotherapy</keyword>
</DOC>